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1  | INTRODUC TION
Poly [ADP‐ribose] polymerase 1 (PARP‐1) is the founding member 
of the PARP family of enzymes which promotes the formation of 
ADP‐ribose polymers (PARs) and their addition to PARP‐1 itself 
and other acceptor proteins in a process referred to as PARylation.1 
PARP‐1 is an abundant nuclear chromatin‐associated protein in‐
volved in a plethora of functions such as DNA repair, recombination, 
cell proliferation and death, inflammation and gene transcription. 
The regulatory functions of PARP‐1 were established after its dis‐
covery four decades ago, and the initially described role in DNA 
repair was followed by confirmation of its involvement in transcrip‐
tional regulation. The link between PARP‐1 and epigenetic events 
was hypothesised in light of its role related to genome stability and 
histone PARylation that leads to chromatin opening resembling the 
outcome of histone acetylation. The regulation of DNA demethyl‐
ation is a newly discovered housekeeping role of PARP‐1, which is 
realized through interaction with ten‐eleven translocation enzymes 
1 (TET1) and the ability of PARP‐1 to PARylate TET1 both covalently 
and noncovalently.2 DNA methylation introduces 5‐methylcytosine 
(5mC) on CpG dinucleotides by the action of DNA methyltransfer‐
ase (DNMT) enzymes (DNMT1, 3A and 3B). Demethylation primarily 
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Abstract
Poly [ADP‐ribose] polymerase 1 (PARP‐1) has an inhibitory effect on C‐X‐C motif 
chemokine 12 gene (Cxcl12) transcription. We examined whether PARP‐1 affects the 
epigenetic control of Cxcl12 expression by changing its DNA methylation pattern. 
We observed increased expression of Cxcl12 in PARP‐1 knock‐out mouse embryonic 
fibroblasts	 (PARP1−/−)	 in	 comparison	 to	 wild‐type	 mouse	 embryonic	 fibroblasts	
(NIH3T3). In the Cxcl12	gene,	a	CpG	island	is	present	in	the	promoter,	the	5′	untrans‐
lated	region	(5′	UTR),	the	first	exon	and	in	the	first	intron.	The	methylation	state	of	
Cxcl12 in each cell line was investigated by methylation‐specific PCR (MSP) and high 
resolution melting analysis (HRM). Both methods revealed strong demethylation in 
PARP1−/−	compared	to	NIH3T3	cells	in	all	four	DNA	regions.	Increased	expression	of	
the Ten‐eleven translocation (Tet)	genes	in	PARP1−/−	cells	indicated	that	TETs	could	be	
important factors in Cxcl12 demethylation in the absence of PARP‐1, accounting for 
its increased expression. Our results showed that PARP‐1 was a potential upstream 
player in (de)methylation events that modulated Cxcl12 expression.
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converts 5mC to 5‐hydroxymethylcyosine (5hmC) and then to 5‐
formylcytosine (5fc) and 5‐carboxylcytosine (5caC) by the action of 
the TET family of dioxygenases (TET1, TET2 and TET3). The DNA 
repair pathways remove 5fc and 5caC, rendering the cytosine un‐
methylated, with these sequential modifications of 5mC comprising 
the active DNA demethylation processes.3,4 5hmC is mainly associ‐
ated with promoter proximal regions or distal regulatory elements 
within CpG islands, which indicates its involvement in transcriptional 
regulation of gene expression.2
We previously reported that PARP‐1 has a pivotal role in sup‐
pressing the Cxcl12 gene promoter5 as a transcriptional regulator 
with a strong binding affinity for the Cxcl12 promoter. CXCL12 is a 
chemokine produced in stromal tissues in multiple organs. CXCL12 
is a potent chemoattractant involved in angiogenesis, leucocyte traf‐
ficking, stem cell homing and in processes including development, 
cell survival, tissue repair and regeneration.6 CXCL12 plays an im‐
portant role in β‐cell differentiation, pancreatic islet genesis and in 
anti‐apoptotic/anti‐necrotic protection of β‐cells from diabetogenic 
agents.7,8 Moreover, CXCL12 is as an important player in various 
diseases (including cancer, inflammatory disorders, atherosclerosis, 
HIV pathology and diabetes),9,10 hence the biological significance of 
methylation‐dependent regulation of the Cxcl12 gene.
Our previous results regarding PARP‐1‐related suppression of 
Cxcl12 raised the question whether this regulatory role of PARP‐1 
controls Cxcl12 expression via an epigenetic mechanism. To address 
this possibility, we examined whether epigenetic events such as pri‐
mary DNA de/methylation drive PARP‐1‐mediated suppression of 
Cxcl12 gene expression.
2  | MATERIAL S AND METHODS
2.1 | Cell culture and treatments
Mouse embryonic fibroblasts NIH3T3 (ATCC‐CRL‐1658) and PARP‐1 
knock‐out	 (PARP1−/−)	 mouse	 embryonic	 fibroblasts	 (derived	 from	
PARP‐1 knock‐out mouse11) cell lines were cultured in high glucose 
Dulbecco's Modified Eagle's medium (DMEM) supplemented with 10% 
foetal bovine serum (FBS), L‐glutamine and penicillin/streptomycin (all 
cell culture reagents were supplied by Biological Industries Israel, Beit 
Haemek Ltd.). Both cell lines were treated with either 1 mmol/L di‐
methyloxalylglycine (DMOG) (Frontier scientific, USA) for 24 hours, or 
with 10 µmol/L L‐ascorbic acid (VitC) (Sigma Aldrich, USA) for 48 hours. 
These concentrations correspond to the EC50 for the two cell lines.
2.2 | Immunoblot analysis
Secreted proteins were precipitated with 13% trichloroacetic acid 
from	the	serum‐free	culture	media	in	which	NIH3T3	and	PARP1−/−	
cells were cultivated for 24 hours. These samples were separated 
by 15% tricine‐sodium dodecyl sulphate‐polyacrylamide gel elec‐
trophoresis (tricine‐SDS‐PAGE) and electrotransferred onto a 
polyvinylidene difluoride membrane. Immunoblotting was per‐
formed using the anti‐CXCL12 primary antibody (FL‐93, Santa Cruz 
Biotechnology, Santa Cruz, CA, USA) incubated overnight at 4°C, 
followed by incubation with horseradish peroxidase‐conjugated 
anti‐rabbit secondary antibody at room temperature for 1 hour. 
Staining was performed by the chemiluminescent technique ac‐
cording to the manufacturer's instructions (Amersham Pharmacia 
Biotech). The intensities of the signals were quantified using 
TotalLab electrophoresis software, ver. 1.10 (Phoretix, Newcastle 
upon Tyne, UK). Statistical significance was estimated by the t test.
2.3 | RNA isolation and real‐time quantitative PCR 
(RT‐qPCR)
The GeneJET RNA Purification Kit (Thermo Fisher Scientific, USA) 
was	used	to	 isolate	total	RNA	from	NIH3T3	and	PARP1−/−	cells,	
either cultured under control condition or treated with DMOG 
or VitC. One microgram of DNase I‐treated RNA was reverse 
transcribed using the RevertAid First Strand cDNA Synthesis 
Kit (Thermo Fisher Scientific, USA), a mix of oligo(dT)18 and ran‐
dom hexamer primers. The QuantStudio 3 Real‐Time PCR sys‐
tem (Applied Biosystems, Carlsbad, CA, USA) and Maxima SYBR 
Green/ROX qPCR Master Mix (Thermo Fisher Scientific, USA) 
were used for RT‐qPCR at the following thermal cycles: initial de‐
naturation at 95°C for 10 minutes and 40 cycles of two‐step PCR 
at 95°C for 15 seconds and at 60°C for 60 seconds. The relative 
expression of target genes was calculated relative to GAPDH (as 
an internal control) by the delta Ct method (2dCt). Statistical tests 
were performed using log2 transformed data and mean values, 
and error bars were back transformed to linear scale for graphs. 
Statistical significance was estimated using paired t test by pair‐
ing	 NIH3T3	 and	 PARP1−/−	 samples	 that	 were	 isolated	 simulta‐
neously. Primer‐BLAST (https://www.ncbi.nlm.nih.gov/tools/
primer‐blast/) was used to design the primers (Table S1) for mu‐
rine sequences stored in GenBank with the following accession 
numbers: Dnmt1 — NC_000075.6 (20907206..20959888, com‐
plement), Dnmt3a — NC_000078.6 (3804986..3914443), Dnmt3b 
— NC_000068.7 (153649165..153687730), Tet1 — NC_000076.6 
(62804570..62887581, complement), Tet2 — NC_000069.6 
(133463677..133545196, complement), Cxcl12 — NC_000072.6 
(117168535..117181368).
2.4 | Isolation of high molecular weight DNA
Cells were lysed in buffer (2 mmol/L EDTA, 10 mmol/L Tris HCl pH 
7.5, 10 mmol/L NaCl, 0.5% SDS) supplemented with 0.04 µg/mL 
proteinase K and the lysate was incubated at 55°C overnight. High 
molecular weight DNA was isolated by ethanol precipitation (with 
cold 75 mmol/L sodium acetate diluted in absolute ethanol) and dis‐
solved in water.
2.5 | Bisulphite conversion of DNA
Bisulphite conversion of genomic DNA isolated from NIH3T3 and 
PARP1−/−	 cells	was	 performed	 using	 the	 EZ‐DNA	methylation	 kit	
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(D5002;	Zymo	Research,	Orange,	CA,	USA)	according	to	the	manu‐
facturer's instructions. Prediction of a CpG island in the Cxcl12 gene 
was performed by EMBOSS Cpgplot bioinformatics tool (https://
www.ebi.ac.uk/Tools/seqstats/emboss_cpgplot/) with standard 
parameters (window size 100; minimum length 200; minimum ob‐
served 0.6; minimum percentage 50%). Genomic DNA sequences 
uploaded for analysis consisted of the whole Cxcl12 gene (NCBI 
ref. NC_000072.6) with the addition of 2000 bp upstream from the 
transcription start site (TSS) marked as +1 (Figure 2).
3  | PCR‐BA SED METHYL ATION ANALYSIS
For DNA methylation analysis, four sets of primers were designed in 
MethPrimer (http://www.urogene.org/methprimer2/) which encom‐
pass four regions of the Cxcl12 gene: part of the promoter (1MU), the 
TSS, the exon‐intron boundary (2MU) and part of the intron (3MU). 
Each set of primers consists of two primer pairs, one specific for 
methylated (M) and the other for unmethylated (U) bisulphite‐con‐
verted sequence. The same primers were used for both methylation‐
specific PCR (MSP) and high resolution melting analysis (HRM) (Table 
S2). In MSP, each primer pair was used in separate reactions while for 
HRM, both M and U primers from the same set were combined in a 
single reaction in order to cover all possible variants in methylation 
status. Both MSP and HRM runs were performed on the QuantStudio 
3 Real‐Time PCR system (Applied Biosystems). For 1MU, 2MU and 
3MU primer sets, PCR was initiated with initial denaturation at 95°C 
for 10 minutes and 40 cycles of two‐step PCR at 95°C for 15 seconds 
and 58°C for 60 seconds. For TSS, the primer set touchdown PCR 
approach was used with initial denaturation at 95°C for 10 minutes 
and each cycle starting with denaturation at 95°C for 30 seconds 
followed by a 30 seconds annealing step at 61°C for the first five 
cycles, at 58°C for the next five cycles and at 55°C for the final 35 
cycles, with each cycle ending with a 60 seconds elongation step at 
72°C. For HRM analysis, after amplification, the additional melt curve 
stage consisted of temperature ramping from 60‐95°C by 0.025°C/s 
with florescence acquisition at each temperature increment. HRM 
Software v3.1 (Applied Biosystems) was employed for end‐product 
analysis. The reaction mixture for MSP contained Maxima SYBR 
Green/ROX qPCR Master Mix (Thermo Fisher Scientific), 60 ng of 
bisulphite‐converted DNA and 2 µmol/L primers in a final volume of 
10 µL. For HRM, 10 µL of reaction contained 5 µL 2 × MeltDoctor 
HRM Master Mix (Applied Biosystems), 0.15 µmol/L of each primer 
and 10 ng of bisulphite‐converted template.
From MSP, we obtained threshold cycle values (Ct) for reac‐
tions with M and U primer pairs for each set. The relative level of 
methylated DNA for each analysed region was expressed using the 
methylation index defined as: 2(demethylated	cycle	Ct)	−	(methylated	cycle	Ct) 12. 
Statistical tests were performed using log2 transformed data; the 
mean values and error bars were back transformed to linear scale 
for graphs. Statistical significance was estimated using paired t 
test	 by	pairing	NIH3T3	 and	PARP1−/−	 samples	 that	were	 isolated	
simultaneously. In HRM analysis, the melting temperatures were 
determined from derivative melting curves and these temperatures 
were used for assessing and comparing overall methylation levels of 
the target regions.
3.1 | In situ nuclear HALO preparation and 
immunostaining
Nuclear HALOs were prepared as previously described.13 In brief, 
nuclei were pelleted onto microscope slides, permeabilized and his‐
tones and soluble proteins were extracted in mild salt extraction 
buffer (0.25 mol/L (NH4)2SO4, 10 mmol/L pipes (pH 6.8), 10 mmol/L 
EDTA, 0.1% digitonin, 0.05 mmol/L spermine and 0.125 mmol/L 
spermidine), which leads to the release of DNA loops which, after 
mild extraction of nuclei, remained attached to the nuclear proteins 
via scaffold/matrix attachment region (S/MAR) sequences. The at‐
tachment patterns are highly reproducible and their dependence on 
the presence of S/MARs has been unambiguously demonstrated. 
For immunostaining, frozen slides were thawed, rehydrated in phos‐
phate buffer solution (PBS) and permeabilized in PBS supplemented 
with 0.25% Triton X‐100. DNA was denatured by 0.01 N HCl at 
37°C for 10 minutes and subsequently neutralized with 100 mmol/L 
Tris HCL (pH 8) for 10 minutes. Next, the slides were incubated in 
70% dimethylformamide supplemented with 0.3 mol/L NaCl and 
30 mmol/L trisodium citrate and blocked for 30 minutes in 1% bo‐
vine serum albumin. Finally, the slides were incubated with primary 
anti‐hmC antibody (Active Motif, USA) at 1:50 dilution, overnight at 
4°C and next with a fluorescein (FITC)‐labelled donkey anti‐rabbit 
secondary antibody (Thermo Fisher Scientific, USA) at 1:400 di‐
lution. The DNA was stained with propidium iodide. Images were 
taken with an Axiocam digital camera attached to the Axio Observer 
Z1	microscope	(Carl	Zeiss	Microscopy	GmbH,	Jena,	Germany),	using	
an appropriate filter.
3.2 | Assessment of global levels of DNA 
methylation
Global methylation levels were measured by the 5‐mC DNA ELISA 
kit	(Zymo	Research,	California,	USA)	according	to	the	manufacturer's	
protocol and guidelines. Statistical significance was estimated using 
one‐way ANOVA with blocking, treating each ELISA plate as a block.
4  | RESULTS
4.1 | The level of Cxcl12 expression in PARP1−/− 
cells compared to NIH3T3
Cxcl12	 expression	 in	 NIH3T3	 and	 PARP1−/−	 cells	 is	 presented	 in	
Figure 1A. Real‐time PCR showed that in the absence of PARP‐1, the 
expression of Cxcl12	 in	 the	PARP1−/−	was	much	higher	 (1.3	×	106 
fold) than in NIH3T3 cells, and this difference was statistically sig‐
nificant (P = 0.009). A similar trend was observed at the protein level, 
examined in cell culture media in which the cells were cultivated 
(P = 0.0057) (Figure 1B).
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4.2 | Methylation pattern of Cxcl12 in NIH3T3 and 
PARP1−/− cells
We confirmed the presence of a CpG island encompassing a part of 
the	promoter,	the	5′	UTR,	the	first	exon	and	part	of	the	first	intron	
of the Cxcl12 gene (Figure 2). To assess the overall methylation 
of this CpG island, we analysed four of its regions by PCR‐based 
methods, MSP and HRM (Figure 3). Primers were designed so that 
amplicons covered part of the promoter, the TSS, the exon‐intron 
boundary and part of the intron. The largest difference in aver‐
age methylation index (calculated from MSP data, Material and 
Methods) was observed for the exon‐intron boundary and the pro‐
moter regions (1172.2 and 995.3 times higher methylation index for 
NIH3T3 respectively), followed by the intron region (262.5 times 
higher methylation index for NIH3T3), with the smallest difference 
observed for the TSS region (75.3 times higher methylation index 
for NIH3T3) (Figure 3). All measured differences of the methyla‐
tion index were statistically significant, with the P = 0.006606 
for the promoter, P = 0.005774 for the TSS, P = 0.00036 for the 
exon‐intron boundary and P = 0.002916 for the intron region. A 
methylation index below 1 indicates that the target sequence is 
predominantly unmethylated while a methylation index above 1 
indicates the opposite, that the target sequence is predominantly 
methylated. Thus, for all four target regions, the calculated meth‐
ylation indices indicated that in NIH3T3, methylation prevailed in 
the analysed regions of the Cxcl12	 gene,	while	 in	PARP1−/−,	 the	
analysed CpGs in this gene were mostly unmethylated. Our MSP 
results were consistent for all analysed regions, however, they 
only represented the level of methylation of CpGs covered by the 
primer pairs (1‐3 CpGs per primer, 17 CpGs in total in all four sets). 
We also analysed the same target regions with HRM, which pro‐
vided information about the methylation of the whole amplicon 
(Figure 3). Unsurprisingly, the results of HRM analysis were in line 
with MSP findings, as the measured melting temperatures were 
consistently	higher	for	NIH3T3	than	for	PARP1−/−	samples	for	all	
four amplicons, indicating that there was an overall higher level 
of methylation in NIH3T3 cells over the entire length of the ana‐
lysed target sequences. Namely, the largest difference in melting 
temperatures was observed for the exon‐intron boundary region 
(5.2°C), followed by the promoter and intron regions (respectively 
2.2°C and 2°C), with the smallest difference observed for the TSS 
region (1.7°C).
F I G U R E  1   A, Relative expresssion 
level of Cxcl12	in	NIH3T3	and	PARP−/−	
cell lines (n = 6). B, Western blot of 
Cxcl12 secreted from NIH3T3 and 
PARP−/−	cell	lines	(n	=	3).	Data	presented	
as mean ± standard error of the mean, 
**P	≤	0.01,	n‐number	of	independent	
experiments
F I G U R E  2   Schematic representation 
of part of murine Cxcl12 gene with marked 
positions of primers used for methylation‐
specific PCR and high‐resolution melting 
analysis analysis
F I G U R E  3   Methylation levels of different parts of Cxcl12	gene	in	PARP−/−	compared	to	NIH3T3	cell	lines	measured	by	methylation‐
specific PCR (MSP) or high‐resolution melting analysis (n = 3). MSP data presented as mean ± standard error of the mean, *P	≤	0.05,	
**P	≤	0.01,	***P	≤	0.001,	n‐number	of	independent	experiments
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4.3 | Examining the global level of DNA methylation 
in NIH3T3 and PARP1−/− cells
To better understand the local differential methylation patterns 
between	 NIH3T3	 and	 PARP1−/−	 cells,	 we	 measured	 the	 global	
levels of DNA methylation and observed a statistically significant 
(P	=	0.04)	decrease	in	DNA	methylation	in	PARP1−/−	compared	to	
NIH3T3 cells (Figure 4A). In order to assess the global DNA dem‐
ethylation level, we looked at 5hmC immunostained HALO prepara‐
tions as 5hmC was the first intermediary product of TET‐mediated 
DNA demethylation. A stronger fluorescent signal was visualized 
in	PARP1−/−	cells	compared	to	NIH3T3	(Figure	4B).	This	suggested	
that PARP‐1 could indeed influence components of the DNA (de)
methylation machinery. We therefore next examined mRNA ex‐
pression of the main players involved in DNA methylation, Dnmt1, 
Dnmt3a, Dnmt3b and in demethylation, Tet1, Tet2 (Figure 4C). Only 
Tet1 and Tet2 mRNA levels exhibited a statistically significant in‐
crease (pTET1 = 0.016 and pTET2 = 0.004) in the absence of PARP‐1 
in	 PARP1−/−	 compared	 to	NIH3T3	 cells,	while	 the	 expression	 of	
Dnmts did not show a significant difference. This finding could ex‐
plain the observed local and global differences in DNA (de)meth‐
ylation levels.
F I G U R E  4   A, Global level of DNA methylation measured by ELISA‐based assay (n = 3). B, Visualisation of 5hmC by immunostaining of 
HALO DNA preparations. C, Relative expresssion levels of Dnmt1, Dnmt3a, Dnmt3b, Tet1, Tet2	in	NIH3T3	and	PARP−/−	cell	lines	(n	=	5).	Data	
presented as mean ± standard error of the mean, *P	≤	0.05,	**P	≤	0.01,	n‐number	of	independent	experiments
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4.4 | The Cxcl12 expression related to the 
activities of TETs
The obtained results pointed to the possibility that TET1 and TET2 
were crucial for enhancing Cxcl12 expression via gene promoter de‐
methylation in the absence of PARP‐1. To check whether TET activity 
is indeed involved in the regulation of Cxcl12 mRNA expression, we 
treated	both	NIH3T3	and	PARP1−/−	cells	with	either	an	activator	of	
TET activity, VitC, or with TET inhibitor, DMOG, and then measured 
Cxcl12 mRNA levels (Figure 5). Statistically significant differences 
between control and treatment conditions were observed only for 
PARP1−/−	 samples	but	 not	 for	NIH3T3.	 In	PARP1−/−	 cells,	Cxcl12 
mRNA expression was significantly increased (P = 0.024) after VitC 
treatment (Figure 5) and also significantly decreased (P = 0.005) 
after DMOG treatment (Figure 5). This indirectly pointed to the in‐
volvement of PARP‐1 in the regulation of TET1/2 activity (indicating 
that in the absence of PARP‐1, TET1 and TET2 are potent enzymes 
exhibiting full enzyme activity).
5  | DISCUSSION
Our previous results based on transfection experiments revealed 
that PARP‐1 plays a role in suppression of the Cxcl12 promoter.5 
Findings presented herein strongly support an inhibitory role of 
PARP‐1 in the regulation of Cxcl12 gene expression. Namely, we 
detected a significantly higher level of Cxcl12 gene expression in 
PARP1−/−	cells	than	in	control	NIH3T3	cells.	This	was	accompanied	
by	increased	protein	abundance	in	the	PARP1−/−	cell	medium,	con‐
firming previously obtained results regarding the ability of PARP‐1 
to down‐regulate Cxcl12 promoter activity. Thus, we extended our 
research to determine whether DNA methylation is integrated in 
PARP‐1‐dependent Cxcl12 suppression.
It is well established that Cxcl12 is epigenetically regulated by 
the methylation of cytosine in CpG dinucleotides located in the pro‐
moter sequence.14,15 Our results revealed pronounced loss of 5mC 
content across all examined regions of the CpG island (that covers 
part of the promoter, TSS, exon/intron boundary and part of the in‐
tron)	in	PARP1−/−	cells,	with	the	most	prominent	change	related	to	
demethylation observed in the exon‐intron boundary and promoter 
regions, with about 1000 times greater methylation indices ascribed 
to	NIH3T3	cells	compared	to	PARP1−/−	cells.	This	pronounced	de‐
methylation status of the Cxcl12	gene	observed	 in	PARP1−/−	cells	
pointed to a potential role of PARP‐1 in DNA demethylation that 
down‐regulated Cxcl12 gene expression.
We suggest that epigenetic regulation of Cxcl12 gene expression 
mediated by PARP‐1 could serve as a therapeutic approach in dis‐
eases associated with CXCL12 down‐regulation or in disease where 
CXCL12 was shown to exert a protective effect. Namely, studies 
have shown protective effects of CXCL12 in atherosclerosis and 
in myocardial infarction‐ischaemia‐reperfusion injury, based on in‐
creased recruitment of progenitor cells and neo‐angiogenesis.16‐18 
Also, CXCL12 possesses an anti‐diabetogenic potential due to 
promotion of beta‐cell survival and its involvement in the regula‐
tion of beta‐cell mass in pancreas, suggesting that manipulation of 
Cxcl12 gene expression could be used in a potential diabetes treat‐
ment.6,19‐22 Furthermore, we recently showed that the DNA methyl‐
ation profile of Cxcl12 gene played an important role in progression 
of periodontitis.23
It was reported that epigenetic down‐regulation of Cxcl12 is 
involved in breast carcinoma, higher proliferation rates of breast 
cancer cells, non‐small cell lung cancer and lymph node metastasis 
development.24 Epigenetic down‐regulation of Cxcl12 expression 
by hypermethylation mediated by DNMT1 was documented in os‐
teosarcoma.25 Additionally, the observation that DNMT1 inhibition 
restored CXCL12 secretion, which consequently suppressed tumour 
growth and retained osteosarcoma progression, was in accordance 
with the overall survival effect connected with increased Cxcl12 
expression.25 Hence, due to the potential antitumor effect of ele‐
vated Cxcl12 expression, the epigenetic targeting of Cxcl12 gene 
expression by a demethylating treatment could have therapeutic 
relevance. Our results revealed that PARP‐1 serves as a potential 
upstream regulator of (de)methylation events that modulate Cxcl12 
F I G U R E  5   Comparison of relative expresssion levels of Cxcl12 
in control conditions vs treatment (Vit C or DMOG) in NIH3T3 
and	PARP−/−	cell	lines	(n	=	3).	Data	presented	as	mean	±	standard	
error of the mean, *P	≤	0.05,	**P	≤	0.01,	n‐number	of	independent	
experiments
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expression. According to literature data, depletion of PAR leads to si‐
lencing of Dnmt1 by hypermethylation, which accounts for defective 
methylation activity and consequently demethylation processes.3,26 
Furthermore, site‐specific demethylation has also been documented 
for gene promoters as a result of PARP‐1 depletion.3,27
According to our results, changes in Dnmts expression were not 
statistically significant. We assumed that the detected decrease in 
the	global	level	of	DNA	methylation	in	PARP1−/−	cells	was	primar‐
ily due to increased expression of Tet genes. It is more likely that 
promotion of TET‐dependent active demethylation takes place in 
PARP1−/−	cells	rather	than	DNMT‐related	suppressed	methylation.	
The observed hypomethylation of mouse Cxcl12	 in	PARP1−/−	cells	
pointed to the involvement of PARP‐1 in the promotion of DNA 
demethylation, and it is tempting to speculate the inhibitory role of 
PARP‐1 on the expression of Tet genes. This is in disagreement with 
the observation that PARP activity positively regulates Tet1 expres‐
sion, which consequently results in initiation of active demethylation 
processes.28,29 This discrepancy may be due to the different exper‐
imental approach, including different cells and methods for evaluat‐
ing the effect of PARP‐1 on Tet1 transcriptional regulation. Namely, 
the cited authors used HEK293T Parp‐1‐silenced (siPARP‐1) cells 
where PARP‐1 was present in a low amount but was not completely 
absent.28 Also, the authors showed that PARP‐1‐dependent regula‐
tion of Tet1 gene expression depended on the level of Tet1 expres‐
sion in a particular cell line. Thus, in cell line MOLT‐3 with high Tet1 
expression, PARP‐1 exerted a stimulatory effect, while in SKW‐3 
cells with low Tet1 expression, there was no effect of PARP‐1 in‐
hibition on Tet1 transcription. Thus, the inconsistency between the 
obtained results could be explained by the fact that we used PARP‐1 
knock‐out cells and a different cell line in which the transcription of 
Tet genes was not so pronounced.
The role of PARP in the control of active demethylation mediated 
by TET enzymes has emerged, implying a high level of complexity of 
PARP/TET cross‐talk. Also, TET is capable of stimulating PARP‐1 ac‐
tivity in vitro, even in the absence of DNA damage; TET1 could be a 
target of PARP‐1 activity by covalent and non‐covalent PARylation 
which affects TET activity differently, activating or inhibiting it re‐
spectively.3 Namely, non‐covalent PARylation of TET1 resulted in 
negative regulation of TET1 activity while covalent PARylation had 
a stimulatory effect on TET1 activity in vitro. The result obtained 
from an experiment with overexpressed, engineered TET1, and a 
specific DNA binding domain showed that PARylation impaired 
TET1 activity in vivo.2 In our study, besides increased expression of 
Tet genes, an increased level of 5hmC as a first intermediary prod‐
uct	in	TET‐mediated	demethylation	in	PARP1−/−	cells	was	detected.	
Immunofluorescence analysis of 5hmC level revealed strong stain‐
ing	in	PARP1−/−	cells.	This	reflected	the	activities	of	TETs	in	mediat‐
ing oxidation of 5mC to 5hmC, which was assumed to be activated 
in	PARP1−/−	cells,	suggesting	a	potential	inhibitory	role	of	PARP‐1	
on the activities of TETs.
Considering the potential involvement of TET‐dependent demeth‐
ylation of Cxcl12, which could be responsible for its elevated expres‐
sion	in	PARP1−/−	cells,	we	performed	experiments	with	TET	enzyme	
activator (VitC) and inhibitor (DMOG) in order to verify whether TET 
activity is involved, at least in part, in the modulation of Cxcl12 gene 
expression. Vitamin C promotes TET‐dependent DNA demethylation 
in embryonic stem cells and increases 5hmC levels through enhanced 
Fe2+ recycling.30‐33 On the other hand, DMOG is a small‐molecule, 
an analogue of 2‐oxoglutarate which inhibits members of 2‐oxogluta‐
rate‐dependent dioxygenases, and is known to impede the enzymatic 
activity of TET enzymes.34,35 In NIH3T3 cells, both treatments did 
not significantly influence Cxcl12 expression. This could be explained 
by the extremely low rate of Cxcl12 expression, which is insufficient 
to allow for the detection of changes in expression. Also, the low 
level of expression of Tet genes and/or PARP‐1 presence may be the 
reasons for the observed insignificant changes in Cxcl12 expression 
under treatments with TET enzyme activator and inhibitor in this cell 
line.	However,	in	PARP1−/−	cells	where	Cxcl12 is more abundant, its 
expression exhibited a tendency to increase in the presence of VitC 
and to decrease upon treatment with DMOG. This suggested that 
Cxcl12 expression could be positively regulated by TET‐mediated de‐
methylation which occurred in the absence of PARP‐1. However, it 
should be noted that VitC and DMOG are not selective activators/
inhibitors of TETs and they can also have other effects. Thus, the ex‐
amination of TET activity in the context of PARP‐1 absence should be 
investigated in more detail in the future.
In conclusion, our study indicates that PARP‐1 maintains the 
hypermethylated state of the Cxcl12 promoter, suppressing its ex‐
pression, and vice versa, disruption of PARP‐1 could mediate events 
such as TET‐dependent hydroxymethylation, leading to Cxcl12 
promoter demethylation and increased expression. Our results sin‐
gled out PARP‐1 as an important upstream regulator of epigenetic 
events such as TET‐dependent demethylation. These findings point 
to the potential regulation of CXCL12 level by targeting PARP/TET 
interplay.
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